---
schema_version: "secwatch.filing_event.v1"
accession: "0001720580-26-000049"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-08-05T20:18:14+00:00"
generated_at: "2026-08-05T20:19:23.084081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q2 net loss $21.4M; prula-cel Phase 1 update expected 3Q2026 with 22 LN/SLE patients

## Summary
- Q2 2026 net loss $21.4M ($1.99/share); cash $118.2M sufficient into 2H2027.
- Phase 1 prula-cel update in 3Q2026: 22 LN/SLE patients with ≥6 months follow-up, 13 with ≥12 months.
- FDA alignment on potential pivotal trial design for LN; start-up activities planned 2H2026.
- Regulatory filing for ADI-212 in mCRPC expected 3Q2026; Phase 1 enrollment anticipated 4Q2026.
- Lloyd Klickstein appointed Interim CMO following departure of Dr. Julie Maltzman.

## SEC filing metadata
- accession: 0001720580-26-000049
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-08-05T20:18:14+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/0001720580-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001720580-26-000049
- JSON: https://secwatch.observer/filing/0001720580-26-000049.json
- Plain text: https://secwatch.observer/filing/0001720580-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.